## Contents

**List of Contributors**  xi
**Preface**  xiii

1  **An Introduction to Pathology Techniques**  1  
    *Elizabeth McInnes*
1.1  Animal Considerations  2
1.2  Necropsy  2
1.3  Lung Inflation with Fixative  5
1.4  Fixation  5
1.5  Making Glass Slides  6
1.5.1 Trimming  6
1.5.2  Tissue Processing  9
1.5.3  Embedding  9
1.5.4  Microtoming  9
1.5.5  Staining  9
1.5.6  Quality Control  11
1.6  Special Histochemical Stains  12
1.7  Decalcification  13
1.8  Immunohistochemistry  13
1.9  Tissue Crossreactivity Studies  15
1.10  Electron Microscopy  15
1.11  In Situ Hybridisation  16
1.12  Laser Capture Microscopy  16
1.13  Confocal Microscopy  16
1.14  Image Analysis  17
1.15  Digital Imaging  17
1.16  Spermatocyte Analysis  17
1.17  Good Laboratory Practice  17
1.18  Inhalation Studies  18
1.19  Continuous-Infusion Studies  18
1.20  Carcinogenicity  19
1.21  Biologicals  19
1.22  The Pathology Report  20
1.23  Conclusion  20
**References**  20
2 Recording Pathology Data 23
Cheryl L. Scudamore
2.1 What is a Pathology Finding? 24
2.2 Standardisation of Pathology Findings 24
2.2.1 Semiquantitative Analysis 24
2.2.2 Nomenclature/Controlled Terminology 26
2.2.3 Ontological Approach 28
2.3 ‘Inconsistencies’ in Pathology Recording 28
2.3.1 Diagnostic Drift 28
2.3.2 Thresholds 28
2.3.3 Lumping versus Splitting 29
2.4 Blind Review 30
2.5 Historical Control Data: Pros and Cons 30
2.6 The Use of Peer Review in Pathology 32
References 32

3 General Pathology and the Terminology of Basic Pathology 35
Elizabeth McInnes
3.1 Cellular Responses to Insults 35
3.2 Inflammation 41
3.3 Circulatory Disturbances 46
3.4 Disorders of Tissue Growth 52
3.5 Tissue Repair and Healing 53
3.6 Neoplasia 54
3.7 Immune System 55
References 57

4 Common Spontaneous and Background Lesions in Laboratory Animals 59
Elizabeth McInnes
4.1 Rats 62
4.2 Mice 63
4.3 Dogs 66
4.4 Minipigs 66
4.5 Non-Human Primates 67
4.6 Rabbits 67
4.7 Experimental Procedures 67
4.8 Causes of Death in Rats and Mice 67
4.9 Conclusion 68
References 69

5 Target Organ Pathology 72
Elizabeth McInnes
5.1 Skin 72
5.2 Eye 76
5.3 Gastrointestinal Tract 78
5.4 Liver 83
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.5</td>
<td>Respiratory System</td>
<td>85</td>
</tr>
<tr>
<td>5.6</td>
<td>Urinary System</td>
<td>89</td>
</tr>
<tr>
<td>5.7</td>
<td>Lymphoreticular System</td>
<td>94</td>
</tr>
<tr>
<td>5.8</td>
<td>Musculoskeletal System</td>
<td>95</td>
</tr>
<tr>
<td>5.9</td>
<td>Cardiovascular System</td>
<td>97</td>
</tr>
<tr>
<td>5.10</td>
<td>Endocrine System</td>
<td>99</td>
</tr>
<tr>
<td>5.11</td>
<td>Reproductive System</td>
<td>102</td>
</tr>
<tr>
<td>5.12</td>
<td>Central and Peripheral Nervous System</td>
<td>104</td>
</tr>
<tr>
<td>5.13</td>
<td>Ear</td>
<td>106</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td></td>
</tr>
</tbody>
</table>

6    **Clinical Pathology** 112

*Barbara von Beust*

6.1    Clinical Pathology in Study Phases and Good Laboratory Practice 112

6.1.1  Preanalytic Phase: Study Plan 113

6.1.2  Analytic Phase: Data Generation 114

6.1.3  Postanalytic Phase: Data Interpretation and Reporting 114

6.1.4  Good Laboratory Practice 114

6.2    What is Measured in Clinical Pathology? 115

6.2.1  Interference by Haemolysis, Lipaemia and Icterus 116

6.3    Haematology 117

6.3.1  Manual and Automated Techniques in Haematology 118

6.3.2  Haematocrit and Red Blood Cell Mass 119

6.3.3  Blood Cells 120

6.3.3.1 Red Blood Cells 120

6.3.3.2 White Blood Cells 122

6.3.3.3 Platelets 124

6.3.4  The Standard Haematology Profile 124

6.3.5  Bone Marrow 125

6.4    Coagulation 125

6.4.1  Standard Coagulation Profile 126

6.4.2  Prothrombin Time 127

6.4.3  Activated Partial Thromboplastin Time 127

6.4.4  Fibrinogen 127

6.5    Clinical Chemistry 127

6.5.1  Metabolites 127

6.5.1.1 Carbohydrate Metabolism 127

6.5.1.2 Protein Metabolism 128

6.5.1.3 Lipid Metabolism 128

6.5.1.4 Metabolism of Haemoglobin 129

6.5.2  Enzymes 129

6.5.3  Electrolytes and Minerals 129

6.5.3.1 Potassium 130

6.5.3.2 Sodium and Chloride 130

6.5.3.3 Calcium and Phosphorus 130

6.5.4  Standard Chemistry Profiles 130

6.5.4.1 Assessment of Liver Function 130
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.5.4.2</td>
<td>Assessment of Kidney Function</td>
<td>130</td>
</tr>
<tr>
<td>6.5.4.3</td>
<td>Assessment of Gastrointestinal Function</td>
<td>131</td>
</tr>
<tr>
<td>6.6</td>
<td>Urinalysis</td>
<td>131</td>
</tr>
<tr>
<td>6.7</td>
<td>Acute-Phase Proteins</td>
<td>131</td>
</tr>
<tr>
<td>6.8</td>
<td>The Biomarker Concept</td>
<td>132</td>
</tr>
<tr>
<td>6.9</td>
<td>Reference Intervals</td>
<td>133</td>
</tr>
<tr>
<td>6.10</td>
<td>Instrumentation, Validation and Quality Control</td>
<td>133</td>
</tr>
<tr>
<td>6.11</td>
<td>Data Analysis and Interpretation</td>
<td>134</td>
</tr>
<tr>
<td>6.12</td>
<td>Reporting</td>
<td>135</td>
</tr>
<tr>
<td>6.13</td>
<td>Food Consumption and Body Weight (Gain)</td>
<td>136</td>
</tr>
<tr>
<td>6.14</td>
<td>Organ Weights</td>
<td>136</td>
</tr>
<tr>
<td>6.15</td>
<td>Examples of Typical Clinical Pathology Profile Changes in Toxicologic Clinical Pathology</td>
<td>136</td>
</tr>
<tr>
<td>6.15.1</td>
<td>Reduced Red Blood Cell Mass due to Chronic Disease</td>
<td>138</td>
</tr>
<tr>
<td>6.15.2</td>
<td>Stress Response</td>
<td>139</td>
</tr>
<tr>
<td>6.15.3</td>
<td>Reduced Red Blood Cell Mass due to Excessive Blood Sampling</td>
<td>139</td>
</tr>
<tr>
<td>6.15.4</td>
<td>Common Artefacts</td>
<td>139</td>
</tr>
<tr>
<td>6.15.4.1</td>
<td>Coagulation</td>
<td>140</td>
</tr>
<tr>
<td>6.15.4.2</td>
<td>Haemolysis and Increased Potassium Concentration</td>
<td>140</td>
</tr>
<tr>
<td>6.15.4.3</td>
<td>Blood in Urine</td>
<td>140</td>
</tr>
<tr>
<td>6.16</td>
<td>Microsampling</td>
<td>140</td>
</tr>
<tr>
<td>6.17</td>
<td>Conclusion</td>
<td>141</td>
</tr>
<tr>
<td>7</td>
<td>Adversity: A Pathologist’s Perspective</td>
<td>145</td>
</tr>
<tr>
<td>7.1</td>
<td>LOAEL, NOEL and NOAEL: Definition</td>
<td>146</td>
</tr>
<tr>
<td>7.2</td>
<td>Adversity</td>
<td>147</td>
</tr>
<tr>
<td>7.3</td>
<td>Determining Adversity using Pathology Findings: Factors to Consider</td>
<td>149</td>
</tr>
<tr>
<td>7.3.1</td>
<td>Severity</td>
<td>149</td>
</tr>
<tr>
<td>7.3.2</td>
<td>Functional Effect</td>
<td>150</td>
</tr>
<tr>
<td>7.3.3</td>
<td>Primary versus Secondary Effects</td>
<td>151</td>
</tr>
<tr>
<td>7.3.4</td>
<td>Physiological Adaptability</td>
<td>152</td>
</tr>
<tr>
<td>7.3.5</td>
<td>Reversibility of the Lesion</td>
<td>152</td>
</tr>
<tr>
<td>7.3.6</td>
<td>Pharmacological Effect</td>
<td>153</td>
</tr>
<tr>
<td>7.4</td>
<td>Communicating NOAEL in Toxicity Studies</td>
<td>153</td>
</tr>
<tr>
<td>7.5</td>
<td>Conclusion</td>
<td>154</td>
</tr>
<tr>
<td>8</td>
<td>Limitations of Pathology and Animal Models</td>
<td>157</td>
</tr>
<tr>
<td>8.1</td>
<td>Limitations of In Vivo Animal Models</td>
<td>157</td>
</tr>
<tr>
<td>8.1.1</td>
<td>Traditional Laboratory Species Used as General Toxicology Models</td>
<td>157</td>
</tr>
<tr>
<td>8.1.2</td>
<td>The Test Article May Not have Sufficient Pharmacological Activity in Routine Toxicology Species</td>
<td>158</td>
</tr>
</tbody>
</table>
8.1.3 The Model May Not Identify Hazards Related to Causation or Exacerbation of Pathology that is Unique to Humans or Undetectable in Animals 159
8.1.4 The Model May Not Identify Hazards with Low Incidence/Low Severity 159
8.1.5 Potential for Misinterpretation of Reversibility/Recovery for Low-Incidence Findings 160
8.1.6 Potential for Over- or Underestimation of the Relationship to Test Article of Findings that have High Spontaneous Incidence in Laboratory Species, but are Relatively Rare in Humans 160
8.1.7 Exclusive Use of Young, Healthy Animals Kept in Ideal Conditions Gives Limited Predictivity for Aged/Diseased Human Populations 161
8.2 Efficacy/Disease Models as Toxicology Models 162
8.3 Limitations of Efficacy/Disease Models as Toxicology Models 164
8.3.1 Lack of Validation as Safety/Toxicology Models 164
8.3.2 Disease Models Rarely Have All the Elements of the Equivalent Human Disease 165
8.3.3 Limited Sensitivity Produced by Increased Interanimal Variability amongst Diseased Animals and/or Low Animal Numbers 165
8.3.4 Lack of Historical Data 166
8.3.5 Risk Associated with Nonregulated Laboratory Conditions 166
8.4 Limitations of Pathology within In Vivo Toxicology Models 167
8.4.1 Anatomic Pathology Evaluation Will Not Identify Hazards with No Morphological Correlates 167
8.4.2 Limitations of Pathology when Evaluating Moribund Animals or Animals Found Dead on Study 168
8.4.3 Limitations of Anatomic and/or Clinical Pathology End Points within other Types of In Vivo Preclinical Safety Study 168
8.4.4 Limitations of Histopathology Related to Sampling Error 169
8.4.5 Limitations of Quantitative Anatomic Pathology 170
8.4.6 Limitations of Pathology Related to Subjectivity and Pathologist Error 173
8.4.7 Anatomic Pathology Error/Missed Findings 173
8.4.8 Subjectivity and Pathologist Variability 175
8.5 Managing Risk Associated with Subjectivity and the Potential for Pathologist Error 176
8.5.1 Choice of Study Pathologist 176
8.5.2 Peer Review 176
8.5.3 Review of the Anatomic Pathology Data 177
8.5.4 Review of Anatomic Pathology Data Interpretation 177
References 179

Glossary 184
Index 187